Contentsodin.ces.edu.co/Contenidos_Web/41025756.pdf33 Ziprasidone 641 John W. Newcomer, M.D. Elise...
9
Contents Contributors XVII Introduction ..................................................... xxxi PART I - -----.-- - -- -- Principlesof Psychopharmacology Robert C. Malenka. M.D.. Ph.D.. Section Editor I Neurotransmitters, Receptors, Signal Transduction, and Second Messengers inPsychiatricDisorders ............................................... 3 Steven T. Szabo, Ph.D. Todd D. Gould, M.D. Husseini K. Manji, M.D., F.R.C.P.C. 2 BasicPrinciples of MolecularBiologyand Genomics.........................59 Jiang-Zhou Yu, M.D., Ph.D. Mark M. Rasenick, Ph. D. 3 Genetics and Genomics 81 Elisabeth B. Binder, M.D., Ph.D. Joseph F. Cube lis, M.D., Ph.D. j 4 Chemical Neuroanatomy of the Primate Brain ............................ 105 Darlene S. Melchitzky, M.S. David A. Lewis, M.D. 5 Electrophysiology.................................................. 135 Anthony A. Grace, Ph.D. J. Arnie! Rosenkranz, Ph.D. Anthony R. West, Ph.D. 6 Animal Models'.................................................... 153 David M. Lyons, Ph.D.
Transcript of Contentsodin.ces.edu.co/Contenidos_Web/41025756.pdf33 Ziprasidone 641 John W. Newcomer, M.D. Elise...
ContentsContributors XVII
Introduction.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xxxi
PART I- -----.-- - -- --
Principlesof PsychopharmacologyRobert C. Malenka. M.D.. Ph.D.. Section Editor
I Neurotransmitters, Receptors, Signal Transduction, and Second Messengersin PsychiatricDisorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Steven T. Szabo, Ph.D.Todd D. Gould, M.D.Husseini K. Manji, M.D., F.R.C.P.C.
2 BasicPrinciples of MolecularBiologyand Genomics. . . . . . . . . . . . . . . . . . . . . . . . .59
Jiang-Zhou Yu, M.D., Ph.D.Mark M. Rasenick, Ph. D.
3 Genetics and Genomics 81
Elisabeth B. Binder, M.D., Ph.D.
Joseph F. Cube lis, M.D., Ph.D.
j 4 Chemical Neuroanatomy of the Primate Brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Darlene S. Melchitzky, M.S.David A. Lewis, M.D.
5 Electrophysiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Anthony A. Grace, Ph.D.J. Arnie! Rosenkranz, Ph.D.Anthony R. West, Ph.D.
6 Animal Models'. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
David M. Lyons, Ph.D.
7 Psychoneuroendocrinology.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 161
Ania Korszun,Ph.D., M.D., M.R.C.Psych.Josephine Astrid Archer, B.Sc.Elizabeth Ann Young, M.D.
8 Principles of Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . 181
C. Lindsay DeVane, Pharm.D.
9 Brain-Immune System Interactions: Relevance to the Pathophysiologyand Treatment of Neuropsychiatric Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
Charles L. Raison, M.D.Monica Kelly Cowles, M.D., M.S.Andrew H. Miller, M.D.
I 0 Brain Imaging in Psychopharmacology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
Ebrahim Haroon, M.D.GiuseppePagnoni,Ph.D..
Christine M. Heim, Ph.D.Gregory S. Berns, M.D., Ph.D.Helen S. Mayberg, M.D.
II Statistics,PlaceboResponse,and ClinicalTrial Designin Psychopharmacology. . . 243Helena C. Kraemer, Ph.D.Alan F. Schatzberg, M.D.
PART II
Classes of Psychiatric Treatments:Animal and Human Pharmacology
K. RangaRamaKrishnan. M.D., and Dennis S. Charney, M.D., Section Editors
Antidepressants and Anxiolytics
I 2 Tricyclic and TetracyclicDrugs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
J.Craig Nelson, M.D.
I 3 Fluoxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289
Janos Zahajszky,M.D.Jerrold F. Rosenbaum, M.D.Gary D. Tollefson, M.D., Ph.D.
14 Sertraline 307
David R. Block, M.D.
Kimberly A. Yonkers, M.D.
Linda L. Carpenter, M.D.
I5 Paroxetine 321
Clifford J. Ehmke, M.D.Charles B. Nemeroff, M.D., Ph.D.
I6 Fluvoxamine 353
EliasAboujaoude, M.D.Lorrin M. Koran, M.D.
I7 CitalopramandS,Citalopram. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363Patrick H. Roseboom, Ph.D.Ned H. Kalin, M.D.
18 MonoamineOxidaseInhibitors.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
K. Ranga Rama Krishnan, M.D.
19 TrazodoneandNefazodone.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .403
Robert N. Golden, M.D.Karon Dawkins, M.D.Linda Nicholas, M.D.
20 Bupropion 415
Anita H. Clayton, M.D.Elizabeth H. Gillespie, D.O.
2 I Mirtazapine 429
Alan F. Schatzberg, M.D.
22 Venlafaxine and Desvenlafaxine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439
Michael E. Thase, M.D.Diane M. Sloan, Pharm.D.
23 DuloxetineandMilnacipran. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 453Sandhaya Norris, M.D.Pierre Blier, M.D., Ph.D.
24 Benzodiazepines 465David V. Sheehan, M.D., M.B.A.
B. Ashok Raj, M.D.
25 BuspironeandGepirone.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487Donald S. Robinson, M.D.Karl Rickels, M.D.Frank D. Yocca, Ph.D.
26 PutativeNew~GenerationAntidepressants.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503Florian Holsboer, M.D., Ph.D.
Antipsychotics
27 ClassicAntipsychoticMedications.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533Henry A. Nasrallah, M.D.Rajiv Tandon, M.D.
28 Clozapine 555
Stephen R. Marder, M.D.Donna A. Wirshing, M.D.
29 Olanzapine 573
Jacob S. Ballon, M.D.Donna A. Wirshing, M.D.S. Charles Schulz, M.D.
30 Quetiapine 599
Peter F. Buckley, M.D.Adriana E. Foster, M.D.
3 I Aripiprazole 613
Zafar A. Sharif, M.D.
Jeffrey A. Lieberman, M.D.
32 Risperidone and Paliperidone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627Donald C. Goff, M.D.
33 Ziprasidone 641
John W. Newcomer, M.D.
Elise M. Fallucco, M.D.
34 Drugs to Treat Extrapyramidal Side Effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .669
Joseph K. Stanilla, M.D.George M. Simpson, M.D.
Drugs for Treatment of BipolarDisorder
35 Lithium 697
Marlene P. Freeman, M.D.Christopher B. Wiegand, M.D.Alan J. Gelenberg, M.D.
36 Valproate 719
Charles L. Bowden, M.D.
37 Carbamazepine and Oxcarbazepine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735
Terence A. Ketter, M.D.Po W. Wang, M.D.Robert M. Post, M.D.
38 Gabapentin and Pregabalin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 767
Mark A. Frye, M.D.Katherine Marshall Moore, M.D.
39 Lamotrigine 779
David E. Kemp, M.D.
David J. Muzina, M.D.
Kerning Gao, M.D., Ph.D.
Joseph R. Calabrese, M.D.
40 Topiramate 795
Susan L. McElroy, M.D.
Paul E. Keck Jr., M.D.
OtherAgents
4 I Cognitive Enhancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 811
Frank W. Brown, M.D.
42 Sedative,Hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
Seiji Nishino, M.D., Ph.D.Kazuo Mishima, M.D., Ph.D.Emmanuel Mignot, M.D., Ph.D.William C. Dement, M.D., Ph.D.
43 Psychostimulants and Wakefulness, Promoting Agents. . . . . . . . . . . . . . . . . . . . . . 843
Christos A. Ballas, M.D.Dwight L. Evans, M.D.David F. Dinges, Ph.D.
44 Electroconvulsive Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 861
William M. McDonald, M.D.Thomas W. Meeks, M.D.W. Vaughn McCall, M.D., M.S.Charles F. Zorumski, M.D.
PART I I I.- - - -- ------ ..- ---- -- ..-. - -- -- --------
Clinical Psychobiology and Psychiatric Syndromes
Davidj. Kupfer,M.D..SectionEditor
45 Neurobiology of Mood Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 903
Charles F. Gillespie, M.D., Ph.D.Steven). Garlow, M.D., Ph.D.Elisabeth B. Binder, M.D., Ph.D.Alan F. Schatzberg, M.D.Charles B. Nemeroff, M.D., Ph.D.
46 Neurobiology of Schizophrenia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 945
Raquel E. Gur, M.D., Ph.D.Steven E. Arnold, M.D.
47 Neurobiology of Anxiety Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 965
Jonathan M. Amiel, M.D.Sanjay J. Mathew, M.D.Amir Garakani, M.D.Alexander Neumeister, M.D.Dennis S. Charney, M.D.
48 Neurobiology of Alzheimer's Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .987Albert A. Davis, B.S.JamesJ. Lah, M.D., Ph.D.Allan I. Levey, M.D., Ph.D.
49 Neurobiology of Substance Abuse and Addiction. . . . . . . . . . . . . . . . . . . . . . . . . 1007
Ashley P. Kennedy, B.S.Clinton D. Kilts, Ph.D.
50 Neurobiology of Eating Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1027
Walter H. Kaye, M.D.Michael A. Strober, Ph.D.
51 Neurobiology of Personality Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1045
Royce Lee, M.D.Emil F. Coccaro, M.D.
52 Neurobiologyof ChildhoodDisorders.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1061
Daniel S. Pine, M.D.
PART IV- -- ". - -- - -- -- -. . ......-- - - - -
Psychopharmacological Treatment
David L. Dunner, M.D., Section Editor
53 Treatmentof Depression. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1081
Catherine Bresee, M.S.Jennifer Gotto, M.D.Mark Hyman Rapaport, M.D.
54 Treatmentof BipolarDisorder.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1113Paul E. Keck Jr., M.D.
Susan L. McElroy, M.D.
55 Treatmentof Schizophrenia.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1135
Tsung-Ung W. Woo, M.D., Ph.D.Carla M. Canuso, M.D.Joanne D. Wojcik, P.M.H.C.N.S.-B.C.Mary F. Brunette, M.D.Alan I. Green, M.D.
5 6 Treatment of Anxiety Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 71
Jonathan R.T. Davidson, M.D.Kathryn M. Connor, M.D., M.H.S.Wei Zhang, M.D., Ph.D.
57 Treatment of Agitation and Aggression in the Elderly. . . . . . . . . . . . . . . . . . . . . . 1201Carl Salzman, M.D.Pierre N. Tariot, M.D.
58 Treatmentof Substance,Related Disorders.. .. . . . . . . . . .. . . . . . . . . . . . . . . . . 1213
Charles P. O'Brien, M.D., Ph.D.
Charles A. Dackis, M.D.
59 Treatmentof EatingDisorders.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1231
W. Stewart Agras, M.D.
60 T rea tmen t of Insomnia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1241Martin Reite, M.D.
61 Treatmentof PersonalityDisorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 1267Daphne Simeon, M.D.Eric Hollander, M.D.
62 Treatment of Psychiatric Emergencies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1287
Margaret B. Weigel, M.D.David C. Purselle, M.D., M.S.Barbara D'Orio, M.D., M.P.AStevenJ. Garlow, M.D., Ph.D.
63 Treatment of Child and Adolescent Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
Karen Dineen Wagner, M.D., Ph.D.Steven R. Pliszka,M.D.
64 Psychopharmacology During Pregnancy and Lactation .. . . . . . . . . . . . . . . . . . . . 13 73
D. JeffreyNewport, M.D.Susana V. Fernandez, B.A.Sandra Juric, B.A.Zachary N. Stowe, M.D.
65 TreatmentDuringLateLife. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . 1413
Steven P. Roose, M.D.Bruce G. Pollock, M.D., Ph.D.D. P. Devanand, M.D.
66 Treatmentof ChronicPainSyndromes.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1441
Kurt Kroenke, M.D.Erin E. Krebs, M.D., M.P.H.Matthew J. Bair, M.D., M.S.
PART Vr -. -- --- - .-- -- ----
Ethical Issues
67 Ethical Considerations in Psychopharmacological Treatment and Research. . . . . . 1477
Jinger G. Hoop, M.D., M.F.A.
Joseph B. Layde, M.D., J.D.Laura Weiss Roberts, M.D., M.A.
Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1497
